
	Where results make sense

Topic: ALZA Corporation

Related Topics

Alza

Lists of companies

List of European companies

Shire Pharmaceuticals

Biovail

List of pharmaceutical companies

AstraZeneca plc

Abbott Laboratories

List of United States companies

Pharmacia

AGFA

Celanese

Cipla

List of Belgian companies

Siemens AG

In the News (Thu 17 Dec 09)

Northern Trust

Marvin Harrison

Peter Chernin

Gary Locke

Match Play

Penelope Cruz

Mickey Rourke

AR Rahman

Danny Boyle

Hugh Jackman

	AEGiS-PRn: ALZA Updates Status of Products Under Development with TDC and Discloses New Technologies at Annual Analyst ... (Site not responding. Last check: 2007-10-13)
		ALZA also announced that it filed an IND earlier this month and is preparing to begin initial clinical trials of its first product incorporating DUROS(TM) human implant technology, which is in development for the treatment of prostate cancer.
		ALZA disclosed that research is underway on a new skin interface technology designed to increase drug transport across the skin and enable delivery of larger molecular-weight compounds, including proteins and peptides.
		ALZA Corporation, headquartered in Palo Alto, Calif., is a leader in the development and commercialization of innovative pharmaceutical products using advanced drug delivery technologies to add medical and economic value to drug therapies.
	www.aegis.com /news/pr/1997/PR970227.html (1181 words)

	Alza Acquires Mycelex Troche In The U.S. From Bayer (Site not responding. Last check: 2007-10-13)
		Bayer Corporation is investing approximately $9 billion in capital expenditures and research and development in its U.S. operations from 1995 through 2000.
		Bayer Corporation, with headquarters in Pittsburgh, is a member of the worldwide Bayer Group, a $32.4 billion chemical and pharmaceutical company based in Leverkusen, Germany.
		ALZA Corporation, headquartered in Palo Alto, Calif., is a leader in the development and commercialization of innovative pharmaceutical products using advanced drug delivery technologies to add medical and economic value to drugtherapies.
	www.bayerus.com /new/1997/7.1.97.html (499 words)

	BioSpace News for Crescendo Pharmaceuticals (Site not responding. Last check: 2007-10-13)
		ALZA Corporation (NYSE: AZA) and Crescendo Pharmaceuticals Corporation (Nasdaq: CNDO) today announced that on Friday, September 29, 2000, ALZA exercised its option to acquire all of the outstanding shares of Crescendo Class A common stock.
		Royalties on ALZA Corporation's sales of Ditropan XL(R) were $1.4 million for the second quarter of 2000, compared to $0.4 million for the second quarter of 1999.
		ALZA Corporation (NYSE: AZA - news) and Crescendo Pharmaceuticals Corporation (Nasdaq: CNDO - news) today announced receipt of an approvable letter from the U.S. Food and Drug Administration (FDA) for Concerta(TM) (methylphenidate HCl) extended-release tablets (CII), a once-daily treatment for children with Attention Deficit Disorder/Attention Deficit Hyperactivity Disorder (ADD/ADHD).
	www.acor.org /drugs/pipeline/companies/news/old/1994.news.orig (885 words)

	ALZA Corporation Jobs: Vault Jobs & Employment Profiles (Site not responding. Last check: 2007-10-13)
		ALZA Corporation was founded in 1968 by Dr. Alejandro Zaffroni, who wanted to fulfill ideas of providing pharmaceutical products that could accurately control the targeting, timing and dosing of therapeutic compounds.
		Other drug delivery systems produced by ALZA include electro-transport systems that push medicine through the skin with electricity, implants that regulate drug delivery within the body for up to a year, depot injections, liposomal technology for i......
		ALZA Corporation employee surveys are collected by Vault editors, Vault Gold Surveys provide detailed information on jobs and employment at specific employers.
	www.vault.com /jobs-company/ALZA-Corporation.html (342 words)

	ALZA - Wikipedia, the free encyclopedia
		ALZA Corporation is a pharmaceutical and medical systems company founded in 1968 by Dr Alejandro Zaffaroni; the company's name is a portmanteau of his name.
		ALZA Corporate Headquarters is in Mountain View, California at the Shoreline Business Park.
		ALZA operates a large-scale clean manufacturing facility in Vacaville, California and another large-scale facility in Cashel, Ireland.
	en.wikipedia.org /wiki/ALZA_Corporation (144 words)

	BioView.com - Corporate Profile - ALZA (Site not responding. Last check: 2007-10-13)
		ALZA Corporation, headquartered in Mountain View, California, is leading the next generation of drug delivery with the world's broadest array of technology platforms, including oral, transdermal, implantable and liposomal technologies.
		In 1968, ALZA was founded by Dr. Alejandro Zaffaroni on the vision that drug delivery technology can add value to all phases of product development and life cycle management.
		ALZA continues to maintain its leadership in drug delivery technology by advancing its broad platform of breakthrough technologies.
	www.bioview.com /job/alza.html (500 words)

	ALZA: Press Release
		Alejandro Zaffaroni, founder of ALZA Corporation, is being honored today with the University of California San Francisco Medal for his extraordinary success in the development of new and innovative drug delivery technologies.
		Zaffaroni founded ALZA in 1968 on the principle that the value of therapeutic compounds can be enhanced by optimizing their delivery into and within the body.
		ALZA has pioneered and continues to lead the development of drug delivery technology, providing innovative solutions that improve health care for millions of patients worldwide.
	www.alza.com /alza/pr_1019752524 (455 words)

	gallerymain1a
		Alza Corporation, Palo Alto, CA In 1969, MBT Architecture designed Alza Corporation's headquarters in Palo Alto, California.
		The project was further complicated by Alza's pressing need to occupy the building in the shortest possible time, since the company had already been formed and had begun recruiting personnel.
		Alza Corporation's headquarters was one of MBT's earliest fasttrack projects.
	www.mbtarch.com /Gallery/gallerymain1a.html (151 words)

	ALZA: Timeline and History
		ALZA Corporation was founded by Dr. Alejandro Zaffaroni in 1968 to realize his vision of sophisticated pharmaceutical products that precisely control the targeting, timing and dosing of therapeutic compounds.
		In pursuing that vision, ALZA has pioneered and continues to lead the development of drug delivery technology.
		Following are some highlights of ALZA's 34-year history of providing innovative solutions that enhance healthcare for millions of patients worldwide.
	www.alza.com /alza/timeline (66 words)

	Alza Announces Approval of Viadur
		Viadur, which has been developed by ALZA on behalf of Crescendo Pharmaceuticals Corporation (Nasdaq: CNDO), is a drug-filled, miniature titanium implant that is placed under the skin in the inner aspects of a patient’s upper arm in an in-office surgical procedure.
		ALZA has exercised its option to obtain a worldwide license for Viadur from Crescendo.
		ALZA Corporation, headquartered in Mountain View, Calif., is a research-based pharmaceutical company with leading drug delivery technologies.
	psa-rising.com /wiredbird/alza06032000.htm (1076 words)

	Bayer to Market ALZA's Viadur™ in U.S. (Site not responding. Last check: 2007-10-13)
		ALZA will receive significant upfront and milestone payments, and manufacturing, patent and trademark payments on a quarterly basis through the third quarter of 2001.
		Bayer Corporation is investing $9 billion in capital expenditures and research and development from 2000 through the year 2004.
		Bayer Corporation, with headquarters in Pittsburgh, Pennsylvania is a member of the worldwide Bayer Group, a $29 billion international life sciences, polymers and specialty chemicals group based in Leverkusen, Germany.
	www.bayerus.com /new/2001/03.20.01c.html (998 words)

	Cygnus v. Alza
		ALZA is the assignee of the '580 patent, which was issued on May 13, 1986.
		ALZA has not expressly threatened to sue Cygnus, however, and its various statements in the record concerning the '580 patent were either made in the setting of licensing discussions with Cygnus or Anaquest or in response to a third party query (the question at the Hambrecht and Quist Healthcare Conference).
		To hold that ALZA's conduct between January of 1989 and May of 1993 constituted "objective circumstances" sufficient to support a reasonable apprehension of suit would be to set at an unacceptably low level the threshold that must be crossed before a district court may exercise declaratory judgment jurisdiction in a patent case.
	www.ll.georgetown.edu /federal/judicial/fed/opinions/95opinions/95-1367.html (4254 words)

	ALZA Corporation Licenses Dapoxetine from PPD GenuPro
		ALZA Corporation Licenses Dapoxetine from PPD GenuPro (December 18, 2000)
		With a corporate mission to help clients maximize the return on their massive R&D investments, PPD provides innovative technologies, therapeutic expertise and comprehensive services for drug discovery and preclinical programs, Phase I-IV clinical development and post-market support.
		ALZA Corporation, headquartered in Mountain View, California, is a research-based pharmaceutical company with leading drug delivery technologies.
	www.ppdi.com /corporate/news/detail.htm?ID=74315 (676 words)

	ALZA: Press Release
		ALZA Corporation (NYSE: AZA) today announced that it will, as of Oct. 1, acquire exclusive Canadian marketing and distribution rights to MacroBID® (nitrofurantoin monohydrate/macrocrystals) and Macrodantinâ (nitrofurantoin macrocrystals) from Procter and Gamble Pharmaceuticals, Inc. MacroBID® and Macrodantin® have been promoted in Canada by Procter and Gamble Pharmaceuticals, Inc. since 1994 and 1972, respectively.
		ALZA Corporation, headquartered in Palo Alto, Calif., is an emerging pharmaceutical company with leading drug delivery technologies.
		ALZA International, Inc., is a wholly-owned subsidiary of ALZA doing business as ALZA Canada, which is based in Markham, Ontario.
	www.alza.com /alza/pr_957366914 (339 words)

	Sample Contracts - Interim Development Agreement - Alza Corp. and BioMedicines Inc. - Competitive Intelligence for ...
		ALZA will indemnify BioMedicines for breach of this warranty, subject to certain limitations to be negotiated in good faith and included in the Agreement.
		ALZA Corporation (“ALZA”) and BioMedicines, Inc. (“BioMedicines”) desire to amend the Interim Development Agreement dated November 8, 2000 between the parties (as amended, the “Agreement”) to revise the description of “Development Costs” in Exhibit A, to extend the period of expanded exclusivity and to provide for a milestone payment.
		ALZA Corporation (“ALZA”) and BioMedicines, Inc. (“BioMedicines”) desire to amend the Interim Development Agreement effective November 8, 2000 between the parties (as amended, the “Agreement”).
	contracts.onecle.com /intarcia/alza.dev.2000.11.08.shtml (3843 words)

	ALZA Corporation Receives Letter From FDA On Dapoxetine Application
		ALZA Corporation is committed to developing safe and effective medicines that address important unmet medical needs.
		ALZA Corporation plans to address questions raised in the FDA letter and continue the global development program.
		ALZA Corporation, headquartered in Mountain View, CA, is leading the next generation of drug delivery, with the world's broadest array of technology platforms, including oral, transdermal, implantable and liposomal technologies.
	www.jnj.com /news/jnj_news/20051026_164127.htm (707 words)

	ALZA Corporation
		ALZA Corporation, headquartered in Mountain View, California, is a leading developer and manufacturer of drug delivery based products for the global healthcare industry.
		ALZA's has the world's broadest array of drug delivery technology and drug targeting platforms, including oral, transdermal, implantable and liposomal technologies and applies its delivery technology to develop and manufacture pharmaceutical products with enhanced therapeutic value for many of the world's leading pharmaceutical and biotechnology companies.
		In 1968, Dr. Alejandro Zaffaroni founded ALZA Corporation on the vision that drug delivery technology can add value to pharmaceutical products by precisely controlling the targeting, timing, and dosing of therapeutic compounds.
	www.biospace.com /company_profile.aspx?CompanyID=1588 (317 words)

	DETE - Tánaiste opens ALZA Ireland’s Cashel Facility
		ALZA Corporation’s technologies include oral delivery systems, transdermal systems and human implantable systems which all control the dosage, timing and release of medication in a range of human medicines.
		ALZA Corporation, a member of the Johnson and Johnson family of companies, is a leading developer of drug delivery-based pharmaceutical products.
		ALZA Corporation is the leading provider of drug delivery solutions with the world's broadest array of technology platforms, including oral, transdermal, implantable and liposomal technologies.
	www.entemp.ie /press/2004/20040907.htm (1162 words)

	ALZA: Community Relations
		ALZA develops innovative drug delivery-based products that address unmet medical needs and help improve the quality of life for patients.
		The creative and passionate individuals at ALZA take pride in the profound impact their work has on the lives of patients and the communities in which we live.
		At ALZA, improving the health and welfare of people around the world is an integral part of our business.
	www.alza.com /alza/community (133 words)

	ALZA Corporation :: ALZA Corporation Resubmits U.S. New Drug Application for IONSYS(TM) (Fentanyl HCl Patient-Activated ...
		ALZA originally submitted the application for licensure of IONSYS(TM) to the FDA in September 2003.
		ALZA Corporation is leading the next generation of drug delivery, with the world's broadest array of technology platforms, including oral, transdermal, implantable and liposomal technologies.
		ALZA's drug delivery technologies have been incorporated in more than 30 products, which are marketed in more than 80 countries worldwide.
	sev.prnewswire.com /health-care-hospitals/20051128/NYM19628112005-1.html (530 words)

	ALZA Corporation Outlines Strategy for Growth in 2001
		ALZA also said it has expanded its urology and primary care sales forces and strengthened its co-promotion partnership with UCB Pharma to extend its reach in the overactive bladder marketplace.
		ALZA is continuing to pursue several new indications for its existing portfolio of products.
		These programs are part of ALZA's strategy to enhance its product portfolio by adding new early-stage projects in the urology, oncology and CNS areas, as well as other possible areas where ALZA believes its technology has the potential to improve current standards of care.
	www.prnewswire.com /cgi-bin/stories.pl?ACCT=104&STORY=/www/story/02-27-2001/0001436618&EDATE= (1263 words)

	Drug Delivery Technology - Article Index
		Because ALZA retains its core competencies in full-scale product development and manufacturing, our partner programs are very strong and will continue to grow.
		ALZA's clinical team then embarked on an aggressive and complex Phase III clinical program, while the manufacturing team worked to transfer the research-scale technology to our manufacturing facility.
		ALZA is working to answer that question, and to develop a product offering a solution that will enable patients to benefit from the drug's therapeutic effects, while reducing side effects.
	www.drugdeliverytech.com /cgi-bin/articles.cgi?idArticle=3 (1276 words)

	Investor Relations - News Releases
		The boards of directors of Johnson & Johnson and ALZA have given approvals to the merger, which is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act and the European Union merger control regulation, and other customary closing conditions.
		ALZA Corporation, headquartered in Mountain View, California, is a research-based pharmaceutical company and a leader in drug delivery technologies.
		A definitive proxy statement/prospectus will be sent to security holders of ALZA Corporation seeking their approval of the transaction.
	www.investor.jnj.com /releaseDetail.cfm?ReleaseID=63833&year=2001 (1209 words)

	CRESA Partners - Corporate Real Estate Service Advisors
		Alza Corporation occupied and owned four pre-paid ground leases that included eight buildings totaling 250,000 square feet in the Stanford Research Park in Palo Alto, California.
		The goal and objective for Alza Corporation was to consolidate into a campus of approximately 500,000 square feet in Mountain View, California and be adjacent to four other existing Alza facilities in Mountain View.
		Alza’s corporate headquarters building was leased under a long-term lease to a major law firm, providing annual earnings per share benefit to Alza.
	www.cresapartners.com /casestudies/Alza.asp (152 words)

	Oregon Judicial Department - Publications
		We are unable to reach the merits of defendants' legal argument because the record reveals a factual dispute regarding whether the note was intended to be an accord and satisfaction for all of the debt that defendants owed plaintiff.
		It was agreed that he would, for purposes of providing Alza Corporation with some security, sign the note for $25,000, with the further understanding that the total amount due and owing was not yet resolved.
		It was not understood, at that time, that Alza Corporation's total bill would be paid pursuant to the terms and conditions of the note.
	www.publications.ojd.state.or.us /A100114.htm (1780 words)

	ALZA Corporation Adopts Stockholder Rights Plan
		The rights generally will not become exercisable until a person or group acquires 15 percent or more of ALZA common stock in a transaction that is not approved in advance by the Board of Directors.
		ALZA Corporation, headquartered in Mountain View, Calif., is a research-based pharmaceutical products company with leading drug delivery technologies.
		ALZA's sales and marketing efforts are currently focused in urology and oncology.
	www.prnewswire.com /cgi-bin/stories.pl?ACCT=104&STORY=/www/story/12-20-1999/0001100420&EDATE= (310 words)

	Johnson & Johnson medical picks Power Wheel's 24 volt industrial mover for its ALZA Corp subsidiary
		ALZA Corporation, a subsidiary of Johnson and Johnson medical (Band-Aids) is located in California.
		ALZA manufactures a variety of medical products, principally transdermal patches for timed delivery of medication to humans.
		ALZA operates a device known as a calender machine which processes plastic film used as a covering for the pharmaceutical products they produce.
	www.powerwheel-usa.com /articles/jjalza.htm (473 words)

Try your search on: Qwika (all wikis)